Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sulzer Medica

This article was originally published in The Gray Sheet

Executive Summary

Spine-Tech unit President Dennis Wallach also will lead the Cardiovascular Prostheses unit following the departure of its leader Terry Marlatt, announced Dec. 4. Wallach had replaced Paul Lunsford at Spine-Tech on Oct. 17 when Lunsford left to become president and CEO of Acorn Cardiovascular (1"The Gray Sheet" Oct. 29, 2001, p. 8). Merging the management of the two Sulzer units will help reduce costs, the firm says. Separately, John Calhoun Wells has been hired by Sulzer and plaintiffs as a mediator to help settle ongoing hip and knee recall cases. Wells was named by the Cleveland federal district court under a Nov. 29 agreement by the two sides in order to prevent the company from being forced into Chapter 11 by suits outside its $783 mil. proposed settlement (2"The Gray Sheet" Dec. 3, 2001, p. 20)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015827

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel